-
公开(公告)号：US5545723A
公开(公告)日：1996-08-13
申请号：US213448
申请日：1994-03-15
Applicant: Susan E. Goelz , Richard L. Cate , E. Pingchang Chow , R. Blake Pepinsky
Inventor： Susan E. Goelz , Richard L. Cate , E. Pingchang Chow , R. Blake Pepinsky
IPC: C12N15/09 , A61K38/00 , A61K38/21 , A61K48/00 , A61P31/12 , A61P35/00 , A61P37/00 , A61P43/00 , C07H21/04 , C07K14/565 , C12N1/21 , C12N15/24 , C12P21/02 , C12R1/19 , C12N15/22
CPC classification number: C07K14/565 , A01K2217/05 , A61K38/00
Abstract: A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods of using those compositions to treat viral infections, cancer or tumors or for immunomodulation.
Abstract translation: 其中phe（F），tyr（Y），trp（W）或他（H））在101位代替val（V）的IFN-β突变蛋白，当根据野生型IFN-β编号时，DNA序列 编码这些IFN-β突变蛋白的重组DNA分子，含有可操作地连接到表达控制序列并能够诱导IFN-β突变蛋白表达的重组DNA分子，用这些重组DNA分子转化的宿主，含IFN-β突变蛋白的药物组合物和 使用这些组合物来治疗病毒感染，癌症或肿瘤或用于免疫调节。
-
公开(公告)号：US6127332A
公开(公告)日：2000-10-03
申请号：US912768
申请日：1997-08-18
Applicant: Susan E. Goelz , Richard L. Cate , E. Pingchang Chow , R. Blake Pepinsky
Inventor： Susan E. Goelz , Richard L. Cate , E. Pingchang Chow , R. Blake Pepinsky
IPC: C12N15/09 , A61K38/00 , A61K38/21 , A61K48/00 , A61P31/12 , A61P35/00 , A61P37/00 , A61P43/00 , C07H21/04 , C07K14/565 , C12N1/21 , C12N15/24 , C12P21/02 , C12R1/19
CPC classification number: C07K14/565 , A01K2217/05 , A61K38/00
Abstract: A IFN-.beta. mutein in which phe (F), tyr (Y), trp (W) or his (H) is substituted for val (V) at position 101, when numbered in accordance with wild type IFN-.beta., DNA sequences encoding these IFN-.beta. muteins, recombinant DNA molecules containing those DNA sequences operatively linked to expression control sequences and capable of inducing expression of an IFN-.beta. mutein, hosts transformed with those recombinant DNA molecules, pharmaceutical compositions containing IFN-.beta. muteins and methods for treating viral infections, cancer or tumors, undesired cell proliferation, or for immunomodulation.
Abstract translation: 其中phe（F），tyr（Y），trp（W）或他（H））在101位代替val（V）的IFN-β突变蛋白，当根据野生型IFN-β编号时，DNA序列 编码这些IFN-β突变蛋白的重组DNA分子，含有可操作地连接到表达调控序列并且能够诱导IFN-β突变蛋白表达的DNA序列的重组DNA分子，用这些重组DNA分子转化的宿主，含IFN-β突变蛋白的药物组合物和 治疗病毒感染，癌症或肿瘤，不期望的细胞增殖或用于免疫调节。
-
公开(公告)号：US5359033A
公开(公告)日：1994-10-25
申请号：US80140
申请日：1993-06-23
Applicant: Richard L. Cate , R. Blake Pepinsky
Inventor： Richard L. Cate , R. Blake Pepinsky
IPC: C12N15/09 , A61K35/48 , A61K38/00 , A61P35/00 , C07K1/22 , C07K14/00 , C07K14/575 , C12N15/12 , C12P21/00 , C12P21/02 , C12P21/06 , C12R1/91 , C07K3/00 , C07K15/00 , C12Q1/00
CPC classification number: C07K14/575
Abstract: This invention relates to cleaved dimers of Mullerian inhibiting substance-like polypeptides. More particularly, this invention relates to such dimers, methods of producing them and methods of using them in the treatment of cancer and tumors, especially those of the female genital tract. The dimers of this invention are also useful in compositions and methods for contraception.
Abstract translation: PCT No.PCT / US89 / 00239 Sec。 371日期1990年7月23日第 102（e）日期1990年7月23日PCT 1989年1月25日PCT PCT。 出版物WO89 / 06695 日本1989年7月27日。本发明涉及Mullerian抑制物质样多肽的切割二聚体。 更具体地说，本发明涉及这样的二聚体，其制备方法和使用它们在治疗癌症和肿瘤，特别是女性生殖道肿瘤的方法。 本发明的二聚体也可用于避孕的组合物和方法。
-
公开(公告)号：US08609407B2
公开(公告)日：2013-12-17
申请号：US13356413
申请日：2012-01-23
Applicant: Sha Mi , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber , Steven D. Miklasz , Christilyn Graff
Inventor： Sha Mi , R. Blake Pepinsky , Zhaohui Shao , Ellen A. Garber , Steven D. Miklasz , Christilyn Graff
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。
-
公开(公告)号：US08425910B2
公开(公告)日：2013-04-23
申请号：US13243795
申请日：2011-09-23
Applicant: Sha Mi , R. Blake Pepinsky , Christilyn Graff
Inventor： Sha Mi , R. Blake Pepinsky , Christilyn Graff
IPC: A61K39/395 , C07K16/28
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.
Abstract translation: 内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体。
-
Patent Agency Ranking
公开(公告)号：US20130096065A1
公开(公告)日：2013-04-18
申请号：US13541302
申请日：2012-07-03
Applicant: Anthony Rossomando , Laura Silvian , R. Blake Pepinsky
Inventor： Anthony Rossomando , Laura Silvian , R. Blake Pepinsky
CPC classification number: C07K14/495 , A61K38/00 , A61K38/185 , A61K47/60 , C07K14/47 , C07K14/4756 , C07K19/00
Abstract: Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal.
Abstract translation: 公开了在所选择的氨基酸残基处具有取代的变体Neburgastin多肽。 在一个或多个选择的氨基酸残基上的取代降低了肝素结合并增加了变异体恩波斯汀多肽的血清暴露。 还公开了使用变体Neburgastin多肽治疗哺乳动物的病症并激活RET受体的方法。
-
公开(公告)号：US08263553B2
公开(公告)日：2012-09-11
申请号：US11573773
申请日：2005-08-18
Applicant: Anthony Rossomando , Laura Silvian , R. Blake Pepinsky
Inventor： Anthony Rossomando , Laura Silvian , R. Blake Pepinsky
CPC classification number: C07K14/495 , A61K38/00 , A61K38/185 , A61K47/60 , C07K14/47 , C07K14/4756 , C07K19/00 , Y02A50/473
Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.
Abstract translation: 公开了在所选择的氨基酸残基处具有取代的变体Neburgastin多肽。 在一个或多个选择的氨基酸残基上的取代降低了肝素结合并增加了变异体恩波斯汀多肽的血清暴露。 还公开了使用变体Neburgastin多肽治疗哺乳动物的病症并激活RET受体的方法。
-
公开(公告)号：US08058406B2
公开(公告)日：2011-11-15
申请号：US12500472
申请日：2009-07-09
Applicant: Sha Mi , R. Blake Pepinsky , Christilyn Graff
Inventor： Sha Mi , R. Blake Pepinsky , Christilyn Graff
IPC: C07K16/28 , A61K39/395 , C12P21/08
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.
Abstract translation: 内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体。
-
公开(公告)号：US20100015131A1
公开(公告)日：2010-01-21
申请号：US12500472
申请日：2009-07-09
Applicant: Sha MI , R. Blake Pepinsky
Inventor： Sha MI , R. Blake Pepinsky
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody
Abstract translation: 内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体
-
10.发明申请公开(公告)号：US20090062199A1
公开(公告)日：2009-03-05
申请号：US12064753
申请日：2006-08-25
Applicant: Dingyi Wen , Daniel H.S. Lee , R. Blake Pepinsky
Inventor： Dingyi Wen , Daniel H.S. Lee , R. Blake Pepinsky
CPC classification number: C07K14/705
Abstract: Nogo receptor 1 (NgR1) is a leucine rich repeat protein that forms part of a signaling complex that modulates axon regeneration. Previous studies have shown that the entire LRR region of Nogo receptor-1, including the C-terminal cap of LRR, LRRCT, is needed for ligand binding, and that the adjacent CT stalk of the Nogo receptor-1 contributes to interaction with its co-receptors. The present invention is directed to the use of certain Nogo receptor-1 and Nogo receptor-2 polypeptides and polypeptide fragments for promoting neurite outgrowth, neuronal survival, and axonal regeneration in CNS neurons. The invention features molecules and methods useful for inhibiting neurite outgrowth inhibition, promoting neuronal survival, and/or promoting axonal regeneration in CNS neurons.
Abstract translation: Nogo受体1（NgR1）是富含亮氨酸的重复蛋白，其形成调节轴突再生的信号复合物的一部分。 以前的研究表明，配体结合需要Nogo受体-1的整个LRR区域，包括LRR的C端帽，LRRCT，Nogo受体-1的相邻CT茎与其co 接受者 本发明涉及某些Nogo受体-1和Nogo受体-2多肽和多肽片段在CNS神经元中促进神经突生长，神经元存活和轴突再生的用途。 本发明的特征在于可用于抑制神经突增生抑制，促进神经元存活和/或促进CNS神经元中的轴突再生的分子和方法。
-
-
-
-
-
-
-
-
-
Search Results
65
records
(took 0.052 seconds)
